The redomestication is a technical event with no operational or financial changes. Monitor for any future conversion of the Series A, B, or C preferred shares into common stock, which could create dilution. The preferred shares were likely issued in connection with prior merger and purchase agreements (dated November 2025) — watch for related filings that may provide context on the holders and conversion triggers.
Price Chart
Executive Summary
Damora Therapeutics completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026, as approved by shareholders on February 9, 2026. The filing also formalizes the adoption of new Cayman Islands governing documents, including certificates of designation for three series of non-voting convertible preferred shares (Series A, B, C) that were authorized by the board in December 2025. This is a technical corporate restructuring with no change to business, management, or operations, and the ordinary shares continue trading on Nasdaq under the same symbol DMRA with a new CUSIP.
Key Facts
- Redomestication from Delaware to Cayman Islands effective July 16, 2026, via plan of conversion approved by shareholders on February 9, 2026.
- New CUSIP number G2646Y104 for ordinary shares, trading under same symbol DMRA on Nasdaq starting July 20, 2026.
- Adopted new Cayman Islands memorandum and articles of association, and certificates of designation for Series A (200 shares), Series B (16,366 shares), and Series C (43,882 shares) non-voting convertible preferred shares, each convertible into 1,000 ordinary shares.
- Entered into indemnification agreements with all directors and executive officers, replacing prior agreements.
- No change in business, management, assets, liabilities, or material contracts; company remains a U.S. corporation for tax purposes.
Financial Impact
No immediate financial impact from redomestication. Potential future dilution from conversion of 60,448 preferred shares into up to 60,448,000 ordinary shares (at 1,000:1 ratio), but preferred shares were authorized in December 2025 and this filing is a formal step under Cayman law.
Risk Factors
- Potential dilution from conversion of preferred shares into up to 60.4 million ordinary shares.
- Change in legal jurisdiction to Cayman Islands may alter shareholder rights and remedies compared to Delaware law.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-308899 |
| Document: dmra-ex3_2.htm | 0001193125-26-308899 |
| Document: dmra-ex3_4.htm | 0001193125-26-308899 |
| Document: dmra-ex3_3.htm | 0001193125-26-308899 |
| Document: dmra-20260716.htm | 0001193125-26-308899 |
| Document: dmra-ex10_1.htm | 0001193125-26-308899 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 14d ago | Institutional Cluster | $20.26 $19.27 | ▼ −4.86% | ▼ −3.37% | $21.53 (+6.29%) |
Sep 28, 2026 28d ago | Insider Buy | $20.75 $20.22 | ▼ −2.55% | ▼ −3.76% | $21.53 (+3.76%) |
Aug 13, 2026 10w ago | EFFECT | $30.73 $30.31 | ▼ −1.37% | ▲ +0.60% | $21.53 (−29.94%) |
Aug 10, 2026 10w ago | Press Release | $30.36 $31.80 | ▼ −4.74% | ▼ −5.15% | $21.53 (+29.08%) |
Jul 20, 2026 13w ago | 8-K | $32.99 $29.44 | ▼ −10.76% | ▼ −9.53% | $21.53 (−34.74%) |
Apr 20, 2026 26w ago | 8-K | $26.82 $24.23 | ▼ −9.66% | ▼ −10.74% | $21.53 (−19.72%) |
Mar 23, 2026 31w ago | Press Release | $23.05 $24.27 | ▲ +5.29% | ▲ +8.86% | $21.53 (−6.59%) |
Mar 19, 2026 31w ago | Press Release | $18.14 $25.50 | ▲ +40.57% | ▲ +42.72% | $21.53 (+18.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers